Login to Your Account



BMS Stumble in HCV Trial Could Prove Gilead's Gain

By Mari Serebrov
Washington Editor

Wednesday, August 8, 2012

In the heat of the race for an interferon-free treatment for hepatitis C virus (HCV), Bristol-Myers Squibb Co. (BMS) stumbled over a serious safety issue in a Phase IIb trial of BMS-986094.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription